Neurocrine Biosciences INC Form 4 insider transactions

Director Shalini Sharp reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.

Director Stephen A. Sherwin reported the acquisition of 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences Inc. on May 22, 2024, which will vest on May 22, 2025.

Director Richard F. Pops acquired 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences, Inc. on May 22, 2024, which will vest on May 22, 2025.

Director George J. Morrow acquired 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences Inc. on May 22, 2024, which will vest on May 22, 2025.

Director Gary A. Lyons acquired stock options and restricted stock units in Neurocrine Biosciences Inc. on May 22, 2024.

Director Leslie V. Norwalk reported the acquisition of Neurocrine Biosciences Restricted Stock Units and Non-Qualified Stock Options on May 22, 2024.

Director Johanna Mercier reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.

Director Shalini Sharp exercised stock options and sold shares of Neurocrine Biosciences (NBIX) under a pre-arranged 10b5-1 trading plan.

Director Richard F. Pops of Neurocrine Biosciences reports the acquisition and disposition of common stock and restricted stock units on May 17, 2024.

Director George J. Morrow exercised stock options in Neurocrine Biosciences on May 17, 2024.

Director Leslie V. Norwalk of Neurocrine Biosciences sold 1,106 shares of common stock at an average price of $141.8173, while also acquiring 2,100 shares through the vesting of restricted stock units.

Director Gary A. Lyons exercised stock options and disposed of 2,100 shares of Neurocrine Biosciences common stock on May 17, 2024.

Director Stephen A. Sherwin exercised stock options, acquiring 4,199 shares of Neurocrine Biosciences common stock on May 17, 2024.

Director Johanna Mercier exercised stock options to acquire 2,100 shares of Neurocrine Biosciences common stock on May 17, 2024.

Director Gary A. Lyons exercised stock options and sold 12,500 shares of Neurocrine Biosciences (NBIX) common stock at an average price of $135.6296, while also correcting a previously overstated beneficial ownership.

Neurocrine Biosciences' Chief Financial Officer, Matt Abernethy, exercised stock options and sold shares of common stock on May 14 and 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares according to a pre-arranged Rule 10b5-1 trading plan.

Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, exercised stock options and sold shares on April 15, 2024, according to a Form 4 filing with the SEC.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, executed stock options and sold shares according to a pre-arranged 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Chief Commercial Officer Eric Benevich of Neurocrine Biosciences exercised stock options and sold shares on March 14, 2024, according to a Form 4 filing with the SEC.

Director George J. Morrow exercised stock options and sold 40,000 shares of Neurocrine Biosciences (NBIX) common stock on March 14, 2024, under a pre-arranged 10b5-1 trading plan.

Richard F. Pops, a director at Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Richard F. Pops exercised stock options and sold Neurocrine Biosciences shares under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the acquisition and disposition of company stock and derivative securities under a pre-arranged trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, reports the acquisition and disposition of common stock and derivative securities, including transactions made under a Rule 10b5-1 trading plan.

Director Leslie V. Norwalk exercised stock options and sold 8,000 shares of Neurocrine Biosciences (NBIX) common stock on February 27, 2024, according to a Form 4 filing with the SEC.